GlassScriptPhysician profile
Larisa Gumerova
NPI 1699061986
$3,106.78
in general payments reported to CMS, 2019-2025
21 companies · $3,089 in 2025
The $3,089 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.62 · 2025: $3,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,978 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,977.67 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $544.44 | 2025 | Austedo Xr, Ajovy |
| Medtronic, INC. | $424.61 | 2025 | Percept PC Brainsense |
| Alexion Pharmaceuticals, INC. | $342.46 | 2025 | Ultomiris |
| Ucb, INC. | $290.82 | 2025 | Briviact, Nayzilam |
| Lundbeck LLC | $237.51 | 2025 | Vyepti |
| Biogen, INC. | $227.84 | 2025 | Vumerity, Leqembi |
| Acadia Pharmaceuticals INC | $219.47 | 2025 | Nuplazid |
| Alnylam Pharmaceuticals INC. | $155.89 | 2025 | Amvuttra |
| Eisai INC. | $125.00 | 2025 | |
| Grifols USA, LLC | $101.40 | 2025 | Gamunex-C |
| Abbvie INC. | $84.53 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $80.32 | 2025 | Rexulti |
| Merz Pharmaceuticals, LLC | $58.18 | 2025 | Inbrija, Xeomin |
| Pfizer INC. | $49.01 | 2025 | |
| Xeris Pharmaceuticals, INC. | $38.25 | 2025 | Keveyis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $31.84 | 2025 | Crexont |
| Neurelis, INC. | $27.12 | 2025 | Valtoco |
| Mdd US Operations, LLC | $18.69 | 2025 | Gocovri |
| Ipsen Biopharmaceuticals, INC | $18.15 | 2025 | Dysport |
| Janssen Pharmaceuticals, INC | $17.62 | 2021 | |
| Lilly USA, LLC | $13.63 | 2025 | Kisunla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larisa Gumerova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.